Literature DB >> 19167422

Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination.

Roberta I Howlett1, Anthony B Miller, George Pasut, Verna Mai.   

Abstract

OBJECTIVE: The purpose of this paper is to outline the short-, medium- and long-term requirements of a strategy to evaluate the impact of HPV immunization and to define a framework to facilitate planning and evaluation.
METHOD: This strategy was developed in Ontario from January to August 2008. Literature review was completed to assess existing material relevant to vaccine evaluation, and HPV vaccine specifically. Scientists and epidemiologists within our organization attended meetings to brainstorm and identify key requirements for vaccine evaluation. Other selected internal and external experts were consulted to review preliminary lists of potential indicators and questions for inclusion in an evaluation strategy.
RESULTS: Results are reported in three sections--literature review, proposed evaluation framework and data requirements.
CONCLUSION: The first vaccine evaluation strategy that integrates primary and secondary prevention of cervical cancer is presented. Among women who are neither screened nor immunized, customized interventions will be required to ensure that they are aware of potential risks and benefits. This evaluation strategy may serve as a useful outline for jurisdictions in Canada and elsewhere. This new paradigm of combined primary and secondary intervention will encourage cooperation for effective evaluation of an integrated approach for control of cervical cancer and other HPV-related disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19167422     DOI: 10.1016/j.ypmed.2008.12.022

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  4 in total

1.  Should We Continue to Perform Pap Smears on Women Who No Longer Have a Cervix?

Authors:  Anthony B Miller
Journal:  Am J Public Health       Date:  2016-11       Impact factor: 9.308

2.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

Review 3.  Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis.

Authors:  Andrea C Tricco; Carmen H Ng; Vladimir Gilca; Andrea Anonychuk; Ba' Pham; Shirra Berliner
Journal:  BMC Infect Dis       Date:  2011-09-05       Impact factor: 3.090

4.  Global challenges of implementing human papillomavirus vaccines.

Authors:  Janice E Graham; Amrita Mishra
Journal:  Int J Equity Health       Date:  2011-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.